To delineate the underlying mechanism whereby anti-SIRPα inhibited HCC progression in TME, we established a spontaneous tumor model and used anti-SIRPα mAb to treat the tumor (Fig. 5A). Here, SIRPA is linked to hepatocellular carcinoma.